Your browser doesn't support javascript.
Repurposing low-dose naltrexone for the prevention and treatment of immunothrombosis in COVID-19.
Pitt, Bertram; Tate, Ashley M; Gluck, David; Rosenson, Robert S; Goonewardena, Sascha N.
  • Pitt B; University of Michigan, Division of Cardiovascular Medicine, Department of Internal Medicine, Ann Arbor, MI 48109, USA.
  • Tate AM; University of Michigan, Division of Cardiovascular Medicine, Department of Internal Medicine, Ann Arbor, MI 48109, USA.
  • Gluck D; Weill Cornell School of Medicine, Department of Internal Medicine, New York, NY 10065, USA.
  • Rosenson RS; Icahn School of Medicine at Mount Sinai, Department of Internal Medicine, New York, NY 10029, USA.
  • Goonewardena SN; University of Michigan, Division of Cardiovascular Medicine, Department of Internal Medicine, Ann Arbor, MI 48109, USA.
Eur Heart J Cardiovasc Pharmacother ; 8(4): 402-405, 2022 06 08.
Article in English | MEDLINE | ID: covidwho-1853023
ABSTRACT
Coronavirus disease 2019 (COVID-19) is characterized by striking dysregulation of the immune system, with evidence of hyperinflammation, an impaired induction of interferons, and delayed adaptive immune responses. In addition to dysfunctional immune responses, thrombosis is a hallmark of severe COVID-19. Because traditional anticoagulation strategies are associated with increased bleeding, novel strategies that address both the immune and thrombotic dysfunction associated with COVID-19 would be of tremendous benefit. In this commentary, we discuss the unique properties of low dose naltrexone (LDN) which could be leveraged to reduce the immune-mediated thrombotic complications in COVID-19. Mechanistically, LDN can blunt innate immune responses and Toll-like receptor (TLR) signaling, reducing interleukin1 (IL-1), tumor necrosis factor-alpha (TNF-α), and interferon (IFN) levels. Because of the immune-mediated thrombotic mechanisms that underlie COVID-19, we hypothesize that the immune-modulating and known pharmacologic properties of LDN could be leveraged as a novel therapeutic strategy in COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Thrombosis / COVID-19 Limits: Humans Language: English Journal: Eur Heart J Cardiovasc Pharmacother Year: 2022 Document Type: Article Affiliation country: Ehjcvp

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Thrombosis / COVID-19 Limits: Humans Language: English Journal: Eur Heart J Cardiovasc Pharmacother Year: 2022 Document Type: Article Affiliation country: Ehjcvp